Casirivimab – Page 2 – Communicable Diseases Research

Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies

Article

Published on 2022-08-282022-11-15
Journal: International Journal of Molecular Sciences [Category] SARS, 변종, 진단,

Compassionate Use of REGEN-COV® in Patients With Coronavirus Disease 2019 (COVID-19) and Immunodeficiency-Associated Antibody Disorders

코로나바이러스 2019(COVID-19) 및 면역결핍 관련 항체 장애 환자에서 REGEN-COV®의 자비로운 사용

Article

Published on 2022-08-242022-09-11
Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 신약개발, 진단,

[키워드] Adverse adverse events antibody Antibody deficiency B-cell B-cell deficiency Casirivimab Chain Reaction Clinical improvement clinical status compassionate use complications COVID-19 COVID-19 infection death Diagnosis disorder event higher risk Imdevimab immunodeficiency immunodeficient patient immunodeficient patients improvement infusion median time Medical conditions monoclonal antibody negative RT-PCR objective outcome oxygenation status Patient patients patients with COVID-19 polymerase chain reaction Quantitative REGEN-COV reported Retrospective analysis RT-PCR Serious Adverse Events subset Treatment viable treatment Viral viral clearance Viral load with COVID-19
[DOI] 10.1093/cid/ciab1059 PMC 바로가기 [Article Type] Article

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles

Omicron 돌연변이는 SARS-CoV-2 바이러스 유사 입자의 감염성을 높이고 항체 중화를 감소시킵니다.

Article

Published on 2022-08-022022-09-11
Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Antibody neutralization Antisera assembly B.1 B.1 lineage B.1.1 bebtelovimab Casirivimab Cell cell entry change convalescent sera coronavirus COVID-19 Delta detectable detrimental dose Effect Efficacy Efficiency eight eight subject elicited ENhance examined Imdevimab individual Johnson & Johnson Johnson & Johnson luciferase Moderna monoclonal antibodies monoclonal antibody Mutation N proteins neutralization neutralization activity neutralization titer Neutralizing antibodies neutralizing antibody omicron Omicron variant Patient Pfizer Pfizer/BioNTech Prevent property reduce reduced respiratory resulting robust SARS-CoV-2 SARS-CoV-2 variant sequence sera severe acute respiratory syndrome Coronavirus Spike protein Spread structural protein structural proteins subjects survivor Vaccine Vaccines variant variants Viral viral infectivity Virus-like particle virus-like particles VLP VLPs
[DOI] 10.1073/pnas.2200592119 PMC 바로가기 [Article Type] Article

Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes

심각한 COVID-19 결과를 예방하는 REGEN-COV 항체 조합의 효과

Article

Published on 2022-08-022022-09-11
Journal: Nature Communications [Category] SARS, 변종, 임상, 진단, 치료법,

Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical Trial

SARS-CoV-2 감염 외래 환자에서 Casirivimab과 Imdevimab COVID-19 항체 조합의 바이러스학적 효능: 2상 용량 범위 무작위 임상 시험

Clinical Trial

Published on 2022-08-012022-09-12
Journal: JAMA Network Open [Category] SARS, 임상, 진단,

[키워드] 95% CI Administered age Asymptomatic average baseline Casirivimab clinical collected COVID-19 death dose double-blind Efficacy efficacy analysis greater Hispanic Hospitalization hypersensitivity reactions Imdevimab in viral intravenous mean difference monoclonal antibody combination outcome Outpatient parallel-group participant Participants Patient patients Phase 2 Phase 3 Placebo placebo-controlled primary end point Randomized randomized clinical trial ranged Reactions reduced reduction reported risk factor SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event seronegative severe COVID-19 study drug Subcutaneous symptomatic symptomatic patient The United States Treatment Viral load were excluded white
[DOI] 10.1001/jamanetworkopen.2022.25411 PMC 바로가기 [Article Type] Clinical Trial

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

회복기 및 백신 혈청 및 단일 클론 항체에 의한 SARS-CoV-2 오미크론 하위 변이체 BA.1 및 BA.2의 제한된 중화

Article

Published on 2022-08-012022-09-11
Journal: EBioMedicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] ACE2 addition antibody BA.1 BA.2 BNT162b2 booster booster dose booster vaccination breakthrough infections Casirivimab Cell Complete convalescent convalescent sera Delta dominant dose education Efficacy elicited exhibited expressing Frankfurt Imdevimab Immunity in vitro study individual infection with SARS-CoV-2 Limited majority median monoclonal antibodies monoclonal antibody monoclonal antibody therapy Mutation neutralisation neutralise neutralising neutralizing capacity omicron Omicron variants reduced Region SARS-CoV-2 sera serum Sotrovimab specific resistance Spike protein supported tested the SARS-CoV-2 the spike protein therapy TMPRSS2 university vaccination Vaccine Vaccines variants variants of SARS-CoV-2 waning immunity
[DOI] 10.1016/j.ebiom.2022.104158 PMC 바로가기 [Article Type] Article

Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials

COVID-19에 대한 새로운 치료법: 더 많은 임상 시험에서 얻은 정보의 가치

Article

Published on 2022-08-012022-09-11
Journal: Value in health : the journal of the International [Category] 임상, 진단,

[키워드] Analysis approval approved Baricitinib benefit Casirivimab clinical clinician Cohort consequence Cost-benefit analysis COVID-19 COVID-19 pandemic decision support techniques Dexamethasone drug approval. effective Emergency use authorization Evidence Health healthcare hospitalized patient hospitalized patients Hydroxychloroquine Imdevimab implementation information interferon interferon beta Interferon beta-1a Lopinavir Lopinavir-ritonavir outcome pandemic Perspective Randomized controlled trial RCT RCTs Remdesivir Research Ritonavir seeking Support therapy threshold Tocilizumab usual care value with COVID-19
[DOI] 10.1016/j.jval.2022.03.016 PMC 바로가기 [Article Type] Article

Real-world effectiveness of casirivimab plus indevimab in a dedicated ambulatory unit created for patients with early COVID-19 during a massive delta variant wave

대규모 델타 변이 파동 동안 초기 COVID-19 환자를 위해 만들어진 전용 보행 유닛에서 카시리비맙과 인데비맙의 실제 효과

Article

Published on 2022-08-012022-09-11
Journal: European Journal of Clinical Microbiology & Infect [Category] COVID19(2023년), SARS, 변종, 진단,

Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1-August 20, 2021): a retrospective observational monocentric study

델타 웨이브(2021년 7월 1일~8월 20일) 동안 단일 클론 항체로 치료한 코로나바이러스 질병 2019(COVID-19)에 대한 백신 접종 및 예방 접종을 받지 않은 환자의 평가: 후향적 관찰 단일 중심 연구

Observational Study

Published on 2022-07-272022-09-11
Journal: BMC Infectious Diseases [Category] MERS, 변종, 임상, 진단,

[키워드] Administered Admission antibody assessment B.1.617.2 Casirivimab casirivimab/imdevimab conducted coronavirus coronavirus disease coronavirus disease 19 COVID-19 COVID-19 infection COVID-19 progression criteria death Delta delta variant Delta wave disease eligibility criteria emergency department EUA feasibility highest Hospital admission Hospitalization Imdevimab mAb median median age Mild-to-moderate monoclonal antibodies monoclonal antibody observational study outcome Patient patients Prevent Primary outcome recipient retrospective risk SARS-CoV-2 variant SARS-CoV-2 variant B.1.617.2 statistically therapy treated Treatment outcome unvaccinated Vaccinated vaccination Vaccination Status
[DOI] 10.1186/s12879-022-07626-6 PMC 바로가기 [Article Type] Observational Study

Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection

병원 내 SARS-CoV-2 델타 변이형 돌발성 감염에 대한 백신 접종 후 항체 평가

Observational Study

Published on 2022-07-252022-09-11
Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-S IgG Anti-spike anti-spike antibody antibody Asymptomatic B.1.617.2 BNT162b2 booster vaccination Breakthrough infection Care Casirivimab characterized collected coronavirus Course Delta variants diagnosed Diagnosis eight estimation geometric mean geometric mean titer GMT hospital Humoral immunity IgG Imdevimab Infection Inpatient LAMP Loop-mediated isothermal amplification lowest measurement Mild mild to moderate mild to moderate severity moderate monoclonal antibody mRNA vaccination nosocomial observational study outbreak public health quantified RBD protein remained respiratory retrospective risk RT-PCR SARS-CoV-2 SARS-CoV-2 delta SARS-COV-2 infection SARS-CoV-2 vaccination Sequencing serological serum sample serum samples Seven severe acute respiratory syndrome Coronavirus severity therapy Treatment uninfected vaccination variant virus viruses was done whole-genome sequencing
[DOI] 10.1371/journal.pone.0272056 PMC 바로가기 [Article Type] Observational Study